Bio-Techne Corporation have agreed to acquire California-based molecular pathology company Advanced Cell Diagnostics for $250 million in cash plus additional potential milestone payments of up to $75M. The acquisition marks
Advanced Cell Diagnostics (ACD) have raised a further $22 million in Series C equity financing, with proceeds to be used to accelerate their entry into the research and clinical diagnostics
